about
Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralizationPotential role of nonstatin cholesterol lowering agentsModel system for the analysis of cell surface expression of human ABCA1.Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus.Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trialEzetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potencyMultiple mechanisms limit the accumulation of unesterified cholesterol in the small intestine of mice deficient in both ACAT2 and ABCA1.Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?Pharmacological management of metabolic syndrome and its lipid complications.Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study.Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic "power station".Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence.Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters.Impact of ezetimibe on atherosclerosis: is the jury still out?Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease.Review of ARBITER 2: extended-release niacin added to statin therapy slows the progression of atherosclerosis. Commentary.New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people?Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats.Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs.The impact of ezetimibe on endothelial function and other markers of cardiovascular risk.Atherosclerosis prevention and treatment in children and adolescents.Therapies for diabetic dyslipidaemia.Do clinical and experimental investigations support an antiatherogenic role for dietary phytosterols/stanols?The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management.Modulation of adhesion molecules by cholesterol-lowering therapy in mononuclear cells from hypercholesterolemic patients.Quantitation of the rates of hepatic and intestinal cholesterol synthesis in lysosomal acid lipase-deficient mice before and during treatment with ezetimibe.ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks.Role of microRNAs 221/222 on statin induced nitric oxide release in human endothelial cells.Entry of hepatitis C virus into the cell: a therapeutic target.Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model.Lipid Uptake, Metabolism, and Transport in the Larval Zebrafish.Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study.LXRβ activation increases intestinal cholesterol absorption, leading to an atherogenic lipoprotein profile.ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells.Blocking HCV entry as potential antiviral therapy
P2860
Q26864485-C9E33BD7-6932-4619-A990-39CB052CC432Q27009231-BDB7C958-8D5A-4F1F-BE0C-002601CCC593Q33520103-D9054963-C319-442B-AFC4-E34BD1B55130Q33890208-AE9C5589-9283-4D19-9D66-18A1DD4FF4F7Q34053876-66029749-D86D-431E-9078-F46A6596ABD6Q34245963-42CC4781-1A47-42FE-B03C-6FFC20AA9540Q34279028-89B82E86-7F38-455B-B383-89191FFEF008Q34353742-B993BADB-03B0-488A-A206-28CFF2AE76D0Q34357426-4BAFEFEF-60FB-48E7-9C46-FD740CDFB08BQ34451067-CB5118CA-E6CA-4DBC-A23B-1E2691F05D7DQ35832189-DF2F1C64-56E4-4AFF-BE2B-242FD5F4DED1Q35837556-67A5A832-8132-4EE5-B08F-4647512A3006Q36071668-A19B025B-0BFC-4092-BF1E-A85C0FC77CF1Q36526924-9CA034D9-B442-46FD-8E8D-820041010376Q36835900-AE8D1137-F153-4E42-A719-F5EE224C41D6Q36956116-5310233C-12B1-46FB-AD22-AE7F6FAF68B4Q37151389-A5B095F8-CECF-4225-80C8-46A089E6444CQ37293985-569A7750-8D70-4778-8BF1-7AF60BD5E0D2Q37427267-917EE20A-957A-4D20-BBA0-EB938205A7B1Q37429025-777EABE1-E147-49E9-9897-3668AF8DE3B7Q37596775-12F20962-3669-466D-B3D3-290122E0D0EBQ37620806-50D01217-F3C6-43DF-BE97-A9B1C43F25C0Q37634194-8C027761-43E2-4422-AF49-FDA5CD9EEFBDQ37732240-FBB28ADC-19BE-4748-A368-A79AFCC2B6F3Q37825945-DC179C80-8BB3-4360-84DD-755CCF9C0C10Q37989422-F38AFC4B-B155-4132-872D-76ED1BCD0E93Q38020942-5CD8A1DA-9C6B-4408-BFC8-1582D1B7E344Q38088216-9765E0E1-A694-435F-B604-543C15D0FDCEQ38883433-384FADDA-1F2C-4296-9EE8-E21955F3C19FQ38891202-2C1AE17C-F17D-48C5-AA49-F40622AFD251Q39052365-3F3D6CB4-D273-4158-A0D7-767EF6497193Q39287679-E34D238E-7F15-466E-806B-FD287A12373FQ42107867-96543D40-B3C2-4E96-805F-80A97EBC1AA5Q43491750-53EAE8C1-DE34-4FE1-B39C-67397587E965Q47165156-1E1F1B51-BECD-40A6-91AB-5DB6932EC946Q51350715-7CF4A5D9-BF1D-4F5C-BF27-8D6A159A720BQ54324443-4DA6D356-69E3-4867-A6AB-13C77577F352Q54382456-2ED025DE-182B-450D-B497-305B1E86164BQ57241788-23A43FC8-2D67-4A2A-BCBD-706CF3AA8B8D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ezetimibe: cholesterol lowering and beyond.
@en
Ezetimibe: cholesterol lowering and beyond.
@nl
type
label
Ezetimibe: cholesterol lowering and beyond.
@en
Ezetimibe: cholesterol lowering and beyond.
@nl
prefLabel
Ezetimibe: cholesterol lowering and beyond.
@en
Ezetimibe: cholesterol lowering and beyond.
@nl
P2093
P2860
P356
P1476
Ezetimibe: cholesterol lowering and beyond.
@en
P2093
Andrew M Tershakovec
David Neff
Harold E Bays
Joanne E Tomassini
P2860
P304
P356
10.1586/14779072.6.4.447
P577
2008-04-01T00:00:00Z